MedTrace Logo

Pomegranate Consumption by Poly-medicated Metabolic Syndrome Patients

NCT04075032 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-09-10

No results posted yet for this study

Summary

The objective is to evaluate whether the medication in polymedicated metabolic syndrome patients could determine the effects of a pomegranate extract on i) metabolic markers, ii) inflammatory markers, and iii) the modulation of the gut microbiota.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Pomegranate extract

Pomegranate extract consumption (900 mg/day) for 4 weeks

OTHER

Placebo

Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks

Sponsors & Collaborators

  • Hospital General Universitario Reina Sofía de Murcia

    collaborator OTHER

  • National Research Council, Spain

    lead OTHER_GOV

Principal Investigators

  • Juan C Espín, PhD · Spanish National Research Council (CSIC)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-10
Primary Completion
2019-07-21
Completion
2019-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04075032 on ClinicalTrials.gov